Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Adverum Biotechnologies, Inc. ADVM
$0.80
-$0.04 (-4.58%)
На 18:00, 12 мая 2023
+150.00%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
82931832.00000000
-
week52high
1.82
-
week52low
0.53
-
Revenue
0
-
P/E TTM
0
-
Beta
0.72698900
-
EPS
-1.43000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 20:05
Описание компании
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Neutral | Neutral | 12 авг 2022 г. |
| Truist Securities | Buy | Hold | 07 июл 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 23 июл 2021 г. |
| Chardan Capital | Neutral | Neutral | 23 июл 2021 г. |
| Cantor Fitzgerald | Neutral | Overweight | 23 июл 2021 г. |
| RBC Capital | Sector Perform | Sector Perform | 11 ноя 2022 г. |
| Chardan Capital | Neutral | Neutral | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Beckman Richard | D | 39061 | 4272 | 19 сент 2022 г. |
| Fischer Laurent | D | 727380 | 41082 | 19 сент 2022 г. |
| Riley Brigit | D | 118734 | 7266 | 19 сент 2022 г. |
| Soparkar Peter | D | 273251 | 13305 | 19 сент 2022 г. |
| Seyedkazemi Setareh | D | 47875 | 6058 | 19 сент 2022 г. |
| Beckman Richard | A | 43333 | 33333 | 14 сент 2022 г. |
| Seyedkazemi Setareh | A | 53933 | 33333 | 14 сент 2022 г. |
| Beckman Richard | A | 35000 | 25000 | 14 сент 2022 г. |
| Fischer Laurent | A | 584978 | 584978 | 14 сент 2022 г. |
| Fischer Laurent | A | 675022 | 675022 | 14 сент 2022 г. |
Новостная лента
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
GlobeNewsWire
10 мая 2023 г. в 16:05
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that members of the executive team will participate in a fireside chat at the 2023 RBC Capital Markets Global Healthcare Conference being held on Wednesday, May 17, 2023 at 3:35 p.m. ET in New York, New York.
Adverum Biotechnologies to Present at Upcoming Investor Conferences
GlobeNewsWire
27 февр 2023 г. в 16:05
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the following upcoming investor conferences:
Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October
PennyStocks
30 сент 2022 г. в 18:32
Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now?
Adverum (ADVM) Doses First Patient in the Mid-Stage wAMD Study
Zacks Investment Research
15 сент 2022 г. в 18:28
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Adverum Biotechnologies to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
08 сент 2022 г. в 16:05
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022.